How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

As organizations race to adopt artificial intelligence, the conversation has increasingly shifted from raw model performance ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

Abstract: Haze reduces the visibility of image content and leads to failure in handling subsequent computer vision tasks. In this paper, we address the problem of single image dehazing by proposing a ...

Nvidia CEO Jensen Huang (R) and SK Group Chairman Chey Tae-won (L) hand out "HBM chip" snacks to reporters during their dinner at a Korean barbecue restaurant in Seoul on June 5, 2026. Nvidia chief ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...

OpenAI says two employees' devices were breached in the recent TanStack supply chain attack that impacted hundreds of npm and PyPI packages, causing the company to rotate code-signing certificates for ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 ...

A decision tree regression system incorporates a set of if-then rules to predict a single numeric value. Decision tree regression is rarely used by itself because it overfits the training data, and so ...